Biotech Values

[oc631]

GILD’s GT3 issue, which the whole world seems willing to overlook, surfaces in this Bloomberg piece on the phase-2 study of Sofosbuvir + Daclatasvir in treatment-experienced patients:

Nice find Dew. The story with Daclatasvir should take a backseat to the more heinous issue of GILD delaying advancement of the interferon-based option for GT3 patients.

Has anyone seen preliminary results from the 2+ year old Sofo/PegRiba study in GT3 treatment-naive patients? Does anyone understand the reasons for the delay? Please post if I'm missing something.

Using Sofo/PegRiba as a comparator, as opposed to the 30-year old GT3 SOC (PegRiba), would put the weak Sofo/Riba combo further into jeopardy. GILD has such a commanding lead in GT3 oral treatment that it's shameful the company doesn't take the time to put together a more viable GT3 oral treatment option. This is about money, not patients.